Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma.
Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma.
复制标题
DOI：
10.1016/j.jdcr.2020.03.007
复制
发表时间：
2020-10
影响因子：
--
通讯作者：
Stoff BK
中科院分区：
文献类型：
--
作者：
Kwon CW;Murthy RK;Kudchadkar R;Stoff BK
食品和药物管理局批准的免疫检查点抑制剂的适应症清单正在迅速增长。皮肤毒性是这些免疫抑制剂最常见的不良事件之一。最常见的毒性反应包括湿疹性皮炎、苔藓样反应和白癜风。还报告了从头BP的发展。1，2，3，4认识到接受免疫治疗的患者可能出现隐匿性免疫大疱性疾病，特别是BP，通常没有紧张的水泡，免疫荧光和酶联免疫吸附试验研究可以在非典型临床表现的检查中获得有价值的信息，我们常规进行这些研究。
DiscussionThere is a rapidly growing list of indications approved by the Food and Drug Administration for immune checkpoint inhibitors. Cutaneous toxicities are among the most common adverse events that can arise with these immunotherapeutic agents. The most frequently observed toxicities include eczematous dermatitis, lichenoid reactions, and vitiligo. Development of de novo BP has also been reported. 1, 2, 3, 4 Recognizing that patients on immunotherapy can present with occult immunobullous diseases, particularly BP, often without tense blisters, immunofluorescence and enzyme-linked immunosorbent assay studies can yield valuable information in the workup of atypical clinical presentations, and we routinely perform them.